Trial · NCT02040532
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Tolerability of Gabapentin | Open-label Gabapentin | # of subjects who tolerated gabapentin | 22 | Participants | |
| Tolerability of Gabapentin | Open-label Gabapentin | # of subjects who did not tolerate gabapentin | 4 | Participants | |
| Reason for Non-tolerability and Discontinuation of Gabapentin | Open-label Gabapentin | Morning sickness and Nausea | 3 | Participants | |
| Reason for Non-tolerability and Discontinuation of Gabapentin | Open-label Gabapentin | Mild Rash | 1 | Participants | |
| Vasomotor Symptoms (VMS) Frequency, Severity, and Bothersomeness During Daytime | Open-label Gabapentin | mean VMS per day at baseline | 4.1 | Full Range 0.2 to 8.5 | vasomotor symptoms (VMS) per day |
| Vasomotor Symptoms (VMS) Frequency, Severity, and Bothersomeness During Daytime | Open-label Gabapentin | mean VMS per day at study completion | 2.2 | Full Range 0 to 6.7 | vasomotor symptoms (VMS) per day |
| Vasomotor Symptoms (VMS) Frequency, Severity, and Bothersomeness During Nighttime | Open-label Gabapentin | mean VMS per night at baseline | 3.5 | Full Range 1.5 to 8.0 | vasomotor symptoms (VMS) per night |
| Vasomotor Symptoms (VMS) Frequency, Severity, and Bothersomeness During Nighttime | Open-label Gabapentin | mean VMS per night at study completion | 1.1 | Full Range 0 to 3.9 | vasomotor symptoms (VMS) per night |
| Severity of Insomnia | Open-label Gabapentin | mean ISI score at baseline | 15.6 | Full Range 8 to 24 | scores on a scale |
| Severity of Insomnia | Open-label Gabapentin | mean ISI score at study completion | 6.0 | Full Range 0 to 18 | scores on a scale |
| Sleep Quality and Disturbances Over Past Month | Open-label Gabapentin | PSQI total score at baseline | 9.6 | Full Range 4 to 17 | scores on a scale |
| Sleep Quality and Disturbances Over Past Month | Open-label Gabapentin | PSQI total score at study completion | 4.9 | Full Range 0 to 12 | scores on a scale |
| Quality of Life-Overall | Open-label Gabapentin | Q-LES-Q scores at baseline | 60.3 | Full Range 30 to 80 | scores on a scale |
| Quality of Life-Overall | Open-label Gabapentin | Q-LES-Q scores at study completion | 61.7 | Full Range 35 to 80 | scores on a scale |
| Quality of Life-Menopause Specific | Open-label Gabapentin | MENQOL scores at baseline | 3.2 | Full Range 1 to 5 | scores on a scale |
| Quality of Life-Menopause Specific | Open-label Gabapentin | MENQOL scores at study completion | 1.9 | Full Range 1 to 3.5 | scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02040532/results